FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1

C Changchen Xiao (Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine) C Chao Wang J Jingyi Wang X Xianpeng Wu (Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).) C Changle Ke J Jinliang Nan (Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).) H Hao Ding Y Yinghui Xu Y Yanna Shi (Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).) J Jing Zhao C Cheng Ni Q Qingnian Liu (Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).) J Jiamin Li S Shuyuan Sheng H Hua Chen (Department of Chemical Engineering, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands) J Jiayue Cai (Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).) T Tonghui Zhao (Key Laboratory of Carbon Materials of Zhejiang Province, College of Chemistry and Materials Engineering) J Jinghai Chen Q Qiming Sun (Innovation Center for Chemical Science, College of Chemistry, Chemical Engineering and Materials Science, Jiangsu Key Laboratory of Advanced Negative Carbon Technologies) B Bin Zhou J Jian’an Wang W Wei Zhu X Xinyang Hu

Abstract

BACKGROUND: Cardiac hypertrophy, as an important pathological change, contributes to heart failure. Recent studies indicate that the mitochondria-associated endoplasmic reticulum membranes (MAMs) play key roles in this pathological process. However, the molecular mechanism remains unclear. This study aims to elucidate the effects and mechanisms of MAM-resident FMO2 (flavin-containing monooxygenase 2) in cardiac hypertrophy and heart failure. METHODS: We performed bulk RNA-sequencing analysis using heart tissue from patients with cardiac hypertrophy and carried out MAM-targeted mass spectrometry analysis using heart tissue from a mouse model of pathological cardiac hypertrophy. In vitro cell culture using neonatal rat cardiomyocytes was used to study how MAMs formation affected cardiomyocyte functions. By generating different genetic mouse models combined with using adeno-associated virus 9 under the cardiac troponin T promoter techniques, we further investigated and confirmed the effects of MAM structure changes on cardiac hypertrophy. RESULTS: We detected an unexpected component of MAMs structure, which was the FMO2, an endoplasmic reticulum–resident protein. FMO2 levels decreased during pathological cardiac hypertrophy. The deletion and overexpression of FMO2 can either worsen or prevent the pathological heart failure progression in vivo, respectively. Our data further demonstrated that FMO2 localizes to MAM structure, where it binds to inositol 1,4,5-trisphosphate type 2 receptor (IP3R2) as a component of the IP3R2–Grp75 (glucose-regulated protein 75)–VDAC1 (voltage-dependent anion channel protein 1) complex, maintaining endoplasmic reticulum–mitochondria contact and regulating mitochondrial Ca 2+ signaling for bioenergetics. Last, we showed that a synthetic peptide-enhancing endoplasmic reticulum–mitochondria contact promoted Ca 2+ transfer and prevented pathological cardiac hypertrophy. CONCLUSIONS: Our findings reveal a key role of FMO2 in myocardial hypertrophy and that FMO2 plays a pivotal role in maintaining MAM structure and function, which may represent a novel mechanism and therapeutic target for cardiac hypertrophy and heart failure.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue 23
Published June 10, 2025
Pages 1667-1685
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (23)

C

Changchen Xiao

Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine

C

Chao Wang

J

Jingyi Wang

X

Xianpeng Wu

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).

C

Changle Ke

J

Jinliang Nan

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).

H

Hao Ding

Y

Yinghui Xu

Y

Yanna Shi

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).

J

Jing Zhao

C

Cheng Ni

Q

Qingnian Liu

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).

J

Jiamin Li

S

Shuyuan Sheng

H

Hua Chen

Department of Chemical Engineering, Delft University of Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands

J

Jiayue Cai

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.X., C.W., J.W., X.W., C.K., J.N., H.D., Y.X., Y.S., J.Z., C.N., Q.L., J.L., S.S., H.C., J.C., T.Z., J.C., Q.S., J.W., W.Z., X.H.).

T

Tonghui Zhao

Key Laboratory of Carbon Materials of Zhejiang Province, College of Chemistry and Materials Engineering

J

Jinghai Chen

Q

Qiming Sun

Innovation Center for Chemical Science, College of Chemistry, Chemical Engineering and Materials Science, Jiangsu Key Laboratory of Advanced Negative Carbon Technologies

B

Bin Zhou

J

Jian’an Wang

W

Wei Zhu

X

Xinyang Hu